Home Kidney Function Blood Tests Uric Acid Blood Test: High, Low, Gout, Kidney Stones, and Kidney Risk

Uric Acid Blood Test: High, Low, Gout, Kidney Stones, and Kidney Risk

By
Vita Library
-
2
Learn how to interpret a uric acid blood test, including high and low levels, gout risk, uric acid kidney stones, CKD associations, treatment targets, and next steps.

A uric acid blood test measures serum urate, the form in which most uric acid circulates at normal blood pH. Uric acid is the final breakdown product of purines, which come from normal cell turnover and from some foods. The kidneys remove much of the body’s urate, so chronic kidney disease (CKD) commonly causes the blood level to rise. High uric acid is also associated with gout and can contribute to uric acid kidney stones, but the same number does not mean the same thing in every person.

Many laboratories use an adult reference range around 3–7 mg/dL, but ranges vary. Monosodium urate solubility is about 6.8 mg/dL under physiologic conditions, helping explain why gout risk rises as serum urate increases. Hyperuricemia does not prove gout, and a normal result during an acute flare does not exclude it. For kidney risk, interpret uric acid with eGFR, urine findings, medications, stone history, and symptoms.

  • High uric acid often results from reduced kidney excretion, especially in CKD or with certain diuretics and other medicines.
  • Hyperuricemia increases the chance of gout, but many people with high urate never develop gout.
  • Uric acid stones depend strongly on persistently acidic urine and low urine volume, not just a high blood uric acid level.
  • Current CKD guidance does not recommend urate-lowering medicine solely to slow CKD in people with asymptomatic hyperuricemia.
  • For established gout treated with urate-lowering therapy, a serum urate target below 6 mg/dL is commonly recommended.

Table of Contents

What the Uric Acid Blood Test Measures

Purines are chemical building blocks found in DNA, RNA, ATP, and many other molecules. When purines are broken down, the body eventually converts them to uric acid. Humans lack the enzyme uricase, so uric acid is the final major product rather than being further converted to allantoin as it is in many other mammals.

At the pH of blood, most uric acid exists in its ionized form, urate. Laboratories may label the test “uric acid” or “serum urate.” In routine clinical use, those names generally refer to the same blood measurement.

The kidneys are central to urate balance. Urate is filtered at the glomerulus and then undergoes extensive reabsorption and secretion in the proximal tubule through specialized transporters. The intestine also contributes to urate elimination. When kidney function declines, renal urate clearance often falls and serum urate rises.

The test may be ordered when gout is suspected, when someone has recurrent kidney stones, during monitoring of urate-lowering medicine, in CKD, or in conditions with rapid cell breakdown such as certain cancers and their treatment. It may also be included in broader metabolic testing.

Serum urate is not a direct filtration test like creatinine-based eGFR. It is influenced by production, dietary intake, kidney and gut excretion, medicines, insulin resistance, hydration, and genetics. A high level can therefore be both a consequence of reduced kidney function and a marker associated with other metabolic conditions.

A blood uric acid test also cannot determine whether crystals are present in a joint or stone. Gout is a crystal disease, and kidney stones are a urinary crystallization problem. The serum value helps estimate risk and guide treatment, but it does not directly visualize those deposits.

Normal Range and Causes of High Uric Acid

Reference intervals vary. Many adult laboratories use values somewhere around 3.0–7.0 mg/dL, often with different upper limits for men and women. Some laboratories use μmol/L; 6.8 mg/dL is approximately 404 μmol/L. Always use the range printed by the laboratory that performed the test.

The frequently cited value of 6.8 mg/dL is not simply a “normal versus abnormal” cutoff. It is approximately the saturation concentration for monosodium urate under physiologic conditions. Above this level, crystal formation becomes more chemically favorable, but temperature, tissue environment, duration of exposure, and individual factors also matter.

Most hyperuricemia results from underexcretion rather than extreme overproduction. Common contributors include:

  • reduced GFR from CKD;
  • loop and thiazide diuretics;
  • low-dose aspirin in some settings;
  • dehydration or volume depletion;
  • insulin resistance and metabolic syndrome;
  • obesity;
  • alcohol, particularly heavy intake;
  • high intake of fructose-sweetened beverages;
  • diets high in some purine-rich meats and seafood;
  • certain transplant medicines, including calcineurin inhibitors.

Overproduction becomes especially important with rapid cell turnover. Leukemia, lymphoma, chemotherapy, tumor lysis syndrome, severe psoriasis, hemolytic disorders, and some rare genetic conditions can sharply increase uric acid production. Tumor lysis can cause acute kidney injury when uric acid and other metabolic abnormalities develop quickly, making it a medical emergency rather than a routine hyperuricemia problem.

The result should be interpreted with medications. A diuretic used for blood pressure or fluid control can raise urate while still being medically necessary. Conversely, medications such as allopurinol, febuxostat, uricosuric agents, and sometimes sodium-glucose cotransporter 2 inhibitors can lower serum urate.

A single high value does not establish the cause. Repeating the level after an acute illness resolves and reviewing kidney function, diet, medicines, alcohol intake, and prior results can be more informative than reacting to one measurement.

Uric Acid and Gout

Gout occurs when monosodium urate crystals deposit in joints or other tissues and trigger inflammation. The classic presentation is sudden severe pain, swelling, warmth, and redness, often in the big toe, ankle, or knee. Repeated attacks can lead to chronic gouty arthritis and tophi, which are larger deposits of urate crystals.

Higher serum urate increases gout risk, especially when the elevation is persistent. However, hyperuricemia is not the same as gout. Many people with urate above the laboratory range never develop a flare, while some people with established gout have a serum urate value within the reference range during an acute attack.

When the diagnosis is uncertain, the most definitive test is identification of monosodium urate crystals in fluid taken from the affected joint or bursa. Ultrasound or dual-energy CT can sometimes provide supportive evidence, but the blood uric acid level alone cannot confirm a flare.

For people who have indications for long-term urate-lowering therapy, treatment is usually adjusted using repeated serum urate measurements. The 2020 American College of Rheumatology guideline recommends a treat-to-target strategy with a serum urate goal below 6 mg/dL. More intensive targets may be used in selected severe cases by some guidelines or specialists, particularly when tophi are present.

Allopurinol is generally a preferred first-line urate-lowering medicine, including in people with moderate-to-severe CKD, when appropriately started at a low dose and titrated. Febuxostat is another xanthine oxidase inhibitor. Drug choice depends on kidney function, previous reactions, cardiovascular history, interacting medicines, and other individual factors.

Treating the urate number and treating an acute gout flare are different tasks. A flare may be treated with colchicine, glucocorticoids, or NSAIDs depending on kidney function and other risks. In CKD, NSAIDs are often less desirable because they can worsen kidney function, and medication doses may require adjustment.

Diet can help but usually does not replace medicine when recurrent gout clearly requires urate-lowering therapy. Weight management, limiting heavy alcohol intake, reducing high-fructose drinks, and moderating high-purine animal foods may lower risk. Extreme dietary restriction is rarely necessary and can make healthy eating harder to sustain.

Uric Acid and Kidney Stones

Uric acid can form stones in the urinary tract, but the chemistry differs from gout. The key factor is often urine pH, not simply the blood uric acid concentration.

Uric acid is much less soluble in acidic urine. When urine pH remains low, a larger fraction of urinary urate exists as poorly soluble uric acid, which can crystallize. Low urine volume increases concentration further. Hyperuricosuria—excess uric acid in the urine—can add to the risk, but many uric acid stone formers do not have extreme urinary uric acid excretion.

Risk is higher with metabolic syndrome, obesity, type 2 diabetes, gout, chronic diarrhea, ileostomy, dehydration, and persistently acidic urine. Hot climates and occupations that promote fluid loss can increase stone risk by lowering urine volume.

A serum uric acid result therefore cannot tell whether a kidney stone is made of uric acid. Stone analysis, imaging characteristics, urine pH, and 24-hour urine testing are more directly useful. Noncontrast CT can detect uric acid stones even though they are often radiolucent on plain X-rays.

Unlike many calcium stones, uric acid stones can often be dissolved medically. Raising urine pH with an alkalinizing treatment such as potassium citrate is a central strategy. Sodium bicarbonate can be used in selected situations. The exact treatment must account for kidney function, potassium level, blood pressure, and other conditions because potassium-containing therapy may be unsafe in some people with CKD.

Adequate fluid intake is important for most stone formers when not contraindicated. The goal is to increase urine volume rather than simply drink a fixed amount regardless of heart or kidney status. People with advanced CKD or heart failure may need individualized fluid advice.

Allopurinol can be useful when uric acid overproduction or hyperuricosuria contributes to stones, but urine alkalinization remains the key treatment for many pure uric acid stones. A 24-hour urine stone risk evaluation can help separate low pH, low volume, hyperuricosuria, and other contributors.

Uric Acid and Chronic Kidney Disease

CKD and hyperuricemia have a two-way association. As GFR falls, the kidneys clear less urate, so serum urate rises. At the same time, observational studies repeatedly find that higher uric acid is associated with future CKD and faster progression.

The difficult question is whether uric acid itself causes enough kidney damage that lowering it in an asymptomatic person will reliably slow CKD. Experimental studies describe plausible mechanisms, including crystal-dependent injury, oxidative stress, endothelial effects, and inflammation. Observational associations are also strong. But treatment trials have not consistently shown that lowering urate prevents CKD progression when gout or another urate-related indication is absent.

This distinction is reflected in the 2024 KDIGO CKD guideline. It recommends uric acid-lowering intervention for people with CKD and symptomatic hyperuricemia, such as gout. It suggests not using urate-lowering drugs solely to delay CKD progression in people with asymptomatic hyperuricemia.

That does not mean high urate should be ignored. It may identify a person with reduced kidney clearance, metabolic risk, or future gout risk. It should prompt review of kidney function, medications, and symptoms. But the presence of an elevated value by itself is not currently a reason to start lifelong allopurinol for “kidney protection.”

People with CKD and gout deserve active gout management. CKD increases gout prevalence and complicates treatment because NSAIDs, colchicine dosing, and urate-lowering medicines require more careful use. Modern management usually favors starting xanthine oxidase inhibitors at a low dose and titrating to the serum urate target rather than leaving the dose permanently low because CKD is present.

The overall kidney picture remains more important than urate alone. A CKD blood test panel, urine albumin-creatinine ratio, blood pressure, diabetes status, and trend in eGFR provide stronger information about CKD severity and progression risk.

Low Uric Acid Levels

Low serum uric acid, or hypouricemia, is less common than hyperuricemia. Mild low values often cause no symptoms and may simply reflect medication effects or individual variation.

Urate-lowering medicines are an expected cause. Allopurinol and febuxostat reduce uric acid production, while uricosuric drugs increase urinary urate excretion. Other medicines can lower urate indirectly.

Low uric acid can also occur when the kidneys excrete unusually large amounts of urate. Proximal tubular disorders such as Fanconi syndrome may cause renal urate wasting along with other abnormalities, including glucose, phosphate, bicarbonate, or amino acid losses in the urine. Rare inherited disorders of urate transport can cause very low serum urate and may be associated with kidney stones or exercise-induced acute kidney injury.

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) can be associated with low uric acid because of altered renal urate handling and water balance. Severe liver disease, low purine intake, and other uncommon metabolic disorders can also contribute.

The clinical importance depends on degree and context. A mildly low result in someone taking allopurinol for gout is very different from an unexpectedly extremely low value with recurrent stones, exercise-related kidney injury, low phosphate, or other tubular abnormalities.

Low urate should not automatically be treated by eating more purine-rich foods. If the value is markedly low or unexplained, the useful next step is to identify the cause through medication review, kidney function testing, electrolytes, urine studies, and other targeted tests.

Interpreting Results and Treatment

Begin with the reason the test was ordered. A uric acid result has different meaning when evaluating a painful swollen joint, monitoring allopurinol, investigating kidney stones, or following CKD.

For suspected gout, consider symptoms and whether a flare is active. A high urate supports risk but does not confirm crystals. If the diagnosis is uncertain—especially with fever, a first severe joint attack, or concern for infection—joint fluid analysis may be necessary.

For known gout on urate-lowering therapy, the trend is more useful. Repeated values above the treatment target may lead to gradual dose titration, while values below 6 mg/dL generally indicate that the biochemical target has been reached. Clinical control of flares and tophi still matters.

For kidney stones, combine serum urate with urine pH, stone analysis, imaging, and often a 24-hour urine collection. A person can have a uric acid stone with a blood urate that is not dramatically high. Likewise, high serum urate does not prove that a stone is made of uric acid.

For CKD, compare uric acid with creatinine, eGFR, urine albumin, potassium, bicarbonate, and the long-term trend. Treat gout and other symptomatic urate disorders, but do not assume that lowering asymptomatic hyperuricemia will necessarily slow CKD.

Urgent evaluation is appropriate when high uric acid appears in the setting of cancer treatment with rapid cell breakdown, sharply worsening kidney function, severe flank pain with fever or obstruction, very low urine output, or other signs of acute illness. Tumor lysis syndrome and obstructed infected stones are emergencies in which uric acid is only one part of the problem.

The practical goal is not to make every uric acid value as low as possible. Treatment should match the clinical condition: prevent crystal deposition in gout, correct urine chemistry in uric acid stone disease, address medication or metabolic contributors, and manage CKD according to proven kidney-protective strategies.

References

Disclaimer

Uric acid results should be interpreted with symptoms, kidney function, medications, urine findings, and the laboratory’s reference interval. Do not start, stop, or change allopurinol, febuxostat, diuretics, alkalinizing medicines, or major dietary restrictions based only on one uric acid result. Seek urgent medical care for severe joint symptoms with fever, cancer-treatment-related metabolic illness, very low urine output, or severe flank pain with fever or urinary obstruction.

RELATED ARTICLESMORE FROM AUTHOR